Podcast Music Movie Game Book
  1. 🎧Podcast
  2. 🎧American Academy of Dermatology
  3. January JAAD: Deucravacitnib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week randomized, double-blinded, placebo-controlled hase 3 POETYK PSO-1 trial

January JAAD: Deucravacitnib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week randomized, double-blinded, placebo-controlled hase 3 POETYK PSO-1 trial

Release Date:

April Armstrong, MD interviewed by Brad Glick, DO, MPH, FAAD

January JAAD: Deucravacitnib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week randomized, double-blinded, placebo-controlled hase 3 POETYK PSO-1 trial
Title
January JAAD: Deucravacitnib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week randomized, double-blinded, placebo-controlled hase 3 POETYK PSO-1 trial
Copyright
Release Date

flashback